Cognition Therapeutics Initiates NIA-Funded SPARC Study of Elayta™ to Assess Changes in Synaptic Density and Cognitive Performance in Alzheimer's Disease Pittsburgh, June 18, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic health and restoration in neurocognitive disorders, today...

Cognition Therapeutics to Present Results of CT1812 Phase 1b/2a Clinical Study as Late Breakers at CTAD Meeting on November 2nd and 4th PITTSBURGH, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...

Cognition Therapeutics CEO Kenneth I. Moch to Present at Ladenburg Thalmann 2017 Healthcare Conference PITTSBURGH, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...